Impact of ruxolitinib on the natural history of primary myelofibrosis: A comparison of the DIPSS and the COMFORT-2 cohorts

Blood

Volumn 123, Issue 12, 2014, Pages 1833-1835

  Passamonti, Francesco ^a   Maffioli, Margherita ^a   Cervantes, Francisco ^b   Vannucchi, Alessandro Maria ^c   Morra, Enrica ^d   Barbui, Tiziano ^e   Caramazza, Domenica ^a   Pieri, Lisa ^c   Rumi, Elisa ^f   Gisslinger, Heinz ^g   Knoops, Laurent ^h   Kiladjian, Jean Jaques ⁱ   Mora, Barbara ^a   Hollaender, Norbert ^j   Pascutto, Cristiana ^f   Harrison, Claire ^k   Cazzola, Mario ^f  

^a OSPEDALE DI CIRCOLO   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF FLORENCE   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f UNIVERSITY OF PAVIA   (Italy)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j NOVARTIS PHARMA AG   (Switzerland)

^k GUY S HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RUXOLITINIB;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MYELOID METAPLASIA; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; JANUS KINASES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES;

EID: 84897528714     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-544411     Document Type: Article

References (20)

1. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
2. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
3. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
4. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-1881.
5. Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120(6):1197-1201.
6. Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008;111(7):3383-3387.
7. Cervantes F, Alvarez-Larrán A, Talarn C, Gómez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118(3):786-790. (Pubitemid 35007383)
8. Guglielmelli P, Barosi G, Pieri L, Antonioli E, Bosi A, Vannucchi AM. JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica. 2009;94(1):144-146.
9. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789-796.
10. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27(6):1322-1327.
11. Passamonti F, Maffioli M, Caramazza D. New generation small-molecule inhibitors in myeloproliferative neoplasms. Curr Opin Hematol. 2012;19(2):117-123.
12. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
13. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
14. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865-1871.
15. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
16. Cervantes F, Vannucchi AM, Kiladjian JJ, et al; COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-4053.
17. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012;120(6):1202-1209.
18. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011;365(15):1455-1457.
19. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer; 2003.
20. Mesa RA, Kiladjian JJ, Verstovsek S, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies [published online ahead of print Aug 2, 2013]. Haematologica. 2013.